| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 141 | PROBIOTIC STRAINS FROM LACTOBACILLUS SALIVARIUS AND ANTIMICROBIAL AGENTS OBTAINED THEREFROM | EP98904350.0 | 1998-02-11 | EP1002051B1 | 2011-01-26 | COLLINS, John, Kevin; O'SULLIVAN, Gerald, Christopher; THORNTON, Gerardine, Mary; O'SULLIVAN, Marian, Mary, Geraldine |
| A strain of Lactobacillus salivarius isolated from resected and washed human gastrointestinal tract inhibits a broad range of Gram positive and Gram negative microorganisms and secretes a product having antimicrobial activity into a cell-free supernatant. The activity is produced only by growing cells and is destroyed by proteinase K and pronase E, the inhibitory properties of the strain and its secretory products being maintained in the presence of physiological concentrations of human bile and human gastric juice. The strain exhibits a broad-spectrum of activity against bacteria including Listeria, Staphylococcus, including methocillin resistant St. aureus (MRSA), and Bacillus, but does not inhibit many closely related lactobacilli. An antimicrobial agent is obtained from the strain which has bacteriocin-like properties. | ||||||
| 142 | Anti-allergy lactic acid bacteria | EP07150079.7 | 2007-12-17 | EP1941892A2 | 2008-07-09 | Su, Wei-Chi; Hsieh, Pei-Shan; Tsai, Yi-Chun; Wu, Chyi-Jang; Chen, Yi-Chun; Kuo, Chung-Wei; Yang, Chiung-Ying |
The invention described relates to novel strains of lactic acid bacteria and their use in anti-allergy. The composition may be in the form of foodstuffs or in the form of pharmaceutical compositions. |
||||||
| 143 | Bifidobacterium in the treatment of inflammatory disease | EP06009910.8 | 2000-01-17 | EP1688481A1 | 2006-08-09 | Collins, John Kevin; O'Sullivan, Gerald Christopher; O'Mahony, Liam; Shanahan, Fergus |
A strain of Bifidobacterium isolated from resected and washed human gastrointestinal tract is significantly immunomodulatory following oral consumption in humans. The strain is useful in the prophylaxis and/or treatment of undesirable inflammatory activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may also be due to cancer. |
||||||
| 144 | (IN VITRO) MODEL FOR GASTROINTESTINAL INFLAMMATION | EP00900790.7 | 2000-01-17 | EP1145001B1 | 2006-05-10 | COLLINS, John, Kevin; O'MAHONY, Liam |
| A strain of Bifidobacterium isolated from resected and washed human gastrointestinal tract is significantly immunomodulatory following oral consumption in humans. The strain is useful in the prophylaxis and/or treatment of undesirable inflammatory activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may also be due to cancer. | ||||||
| 145 | FISHES TREATED WITH LACTIC ACID BACTERIUM CULTURE MEDIUM HAVING ANTIBACTERIAL AND ANTIXOIDATIVE EFFECTS | EP03810635.7 | 2003-11-06 | EP1559324A1 | 2005-08-03 | DOUMOTO, Nobuhiko, Nippon Suisan Kaisha, Ltd.; TAKAHASHI, Akiko, Nippon Suisan Kaisha, Ltd.; NASU, Masayuki, Nippon Suisan Kaisha, Ltd.; OBA, Takahiro, Nippon Suisan Kaisha, Ltd. |
Fish and shellfish meat whose color tone is well preserved, particularly no Listeria contamination and in which discoloration is effectively prevented, and smoked products prepared from such fish and shellfish meat are provided. Fish meat which is no Listeria contamination and in which discoloration is prevented can be obtained by treating the meat with a cultivation medium used for cultivating lactic acid bacteria. Specifically, the meat is immersed preferably in a sterilized or disinfected cultivation medium used for cultivating a lactic acid bacterium having antibacterial and anti-oxidative effects, or two lactic acid bacteria in combination, one having antibacterial effect and the other anti-oxidative effect. Combinational use of Lactobacillus sake D-1001 (FERM P-11708 or IPOD FERM BP-08544) and Lactococcus lactis IFO 12007 is preferred. The fish meat is preferably derived from salmon, trout or cod, and the inventive method is particularly effective for fish meat containing astaxanthin. |
||||||
| 146 | VITAL CELL PREPARATIONS CONTAINING LACTIC ACID BACTERIUM AS THE ACTIVE INGREDIENT AND LACTIC ACID BACTERIUM-CONTAINING FOODS | EP02708726.1 | 2002-03-29 | EP1498039A8 | 2005-06-22 | KOGA, Yasuhiro |
Disclosed is a live bacterium preparation or food containing a lactic acid bacterium comprising a lactic acid bacterium, Lactobacillus salivarius, as an active ingredient. There is provided a live bacterium preparation and food containing a lactic acid bacterium that can prevent onset, recurrence and exacerbation of periodontal disease and/or dental caries caused by periodontopathic bacteria and cariogenic bacteria and can prevent generation of halitosis and maintain pH of saliva at a physiologically normal level by normalizing intraoral microflora. |
||||||
| 147 | BILE ACID ABSORBENT/ADSORBENT | EP02755899 | 2002-08-09 | EP1421945A4 | 2005-06-22 | YOKOTA ATSUSHI; TOMITA FUSAO; SAYAMA KOUJI; HUKUMORI YASUNORI |
| The present invention provides a bile acid absorbent/adsorbent comprising as active ingredients a lactic acid bacterium having a property of incorporating bile acids into the cell in the presence of an oligosaccharide and of no releasing them out of the cells, and the oligosaccharide. The lactic acid bacterium includes Lactobacillus salivarius ssp. salicinius strain JCM1044, Bifidobacterium breve strain JCM1192, etc. The oligosaccharide includes raffinose, kestose, nystose, trehalose, etc. The bile acid adsorbent is in a form of oral formulation, or eatables and drinkables, etc. The bile acid absorbent/adsorbent can be utilized as cholesterol lowering agents or colorectal cancer inhibitors. |
||||||
| 148 | CARRIER, METHOD OF MANUFACTURING A CARRIER AND AN ELECTRONIC DEVICE | EP03715164.4 | 2003-04-10 | EP1500137A1 | 2005-01-26 | GROENHUIS, Roelf, A., J.; DIJKSTRA, Paul; SCHRIKS, Cornelis, G.; VAN DE WATER, Peter, W., M. |
| The carrier ( 30 ) comprises a first etch mask ( 14 ), a first metal layer ( 11 ), an intermediate layer ( 12 ), a second metal layer ( 13 ) and a second etch mask ( 17 ). Both the first and the second etch mask ( 14, 17 ) can be provided in one step by means of electrochemical plating. After the first metal layer ( 11 ) and the intermediate layer ( 12 ) have been patterned through the first etch mask ( 14 ), an electric element ( 20 ) can be suitably attached to the carrier ( 30 ) using conductive means. In this patterning operation, the intermediate layer ( 12 ) is etched further so as to create underetching below the first metal layer ( 11 ). After the provision of an encapsulation ( 40 ), the second metal layer ( 13 ) is patterned through the second etch mask ( 17 ). In this manner, a solderable device ( 10 ) is obtained without a photolithographic step during the assembly process. | ||||||
| 149 | PROBIOTICS PRODUCTS CONTAINING LACTIC ACID BACTERIUM | EP01958512 | 2001-08-27 | EP1312667A4 | 2005-01-19 | KATO AZUSA; NAKAYA SEIGO; SUZUKI N; HIRATA H |
| Probiotics products containing as the active ingredient a lactic acid bacterium belonging to Lactobacillus salivarius which is excellent in the ability to adhere to mucosal epithelial cells, proliferation properties and acid-fastness; compositions for preventing and/or treating digestive diseases containing the same as the active ingredient; compositions for preventing and/or treating urogenital infections containing the same as the active ingredient; and a novel Lactobacillus salivarius strain which is excellent in the ability to adhere to mucosal epithelial cells, proliferation properties and acid-fastness. The above-described lactic acid bacterium, the probiotics products containing the same as the active ingredient and the compositions for preventing and/or treating digestive diseases or urogenital infections can exert a high probiotics function against discharge from the digestive tract or the urogenital organs. | ||||||
| 150 | Novel lactobacilli strains useful in the treatment of disorders of the gastrointestinal system | EP98103109.9 | 1998-02-23 | EP0861905B1 | 2004-11-24 | Pedraglio, Gabriele |
| Novel lactobacilli useful for the treatment of disorders of the gastrointestinal system, more particularly novel strains of Lactobacillus Paracasei and Lactobacillus Salivarius, the process for the preparation thereof, pharmaceutical compositions, dietary supplements and alimentary products containing them. | ||||||
| 151 | PROBIOTICS PRODUCTS CONTAINING LACTIC ACID BACTERIUM | EP01958512.4 | 2001-08-27 | EP1312667A1 | 2003-05-21 | KATO, Azusa, c/o Wakamoto Pharmaceutical Co., Ltd; NAKAYA,Seigo, c/o Wakamoto Pharmaceutical Co., Ltd; SUZUKI, N., c/o Wakamoto Pharmaceutical Co., Ltd.; HIRATA, H, /o Wakamoto Pharmaceutical Co., Ltd. |
The present invention provides a probiotics product comprising, as an effective component, lactic acid bacteria belonging to Lactobacillus salivarius possessing high adhesiveness to mucous membrane, a high proliferation ability and a high resistance to acids, a composition for preventing and/or treating digestive tract's diseases comprising the probiotics product as an effective component and a novel Lactobacillus salivarius strain possessing high adhesiveness to mucous membrane, a high proliferation ability and a high resistance to acids. The lactic acid bacteria and the probiotics product and the composition for preventing and/or treating digestive tract's diseases, which contain the lactic acid bacteria as an effective component, according to the present invention can sufficiently show their probiotics functions without being easily discharged from the digestive tract and urinogenital organs. |
||||||
| 152 | Zum Reifen von Rohwurst geeignete Mikroorganismen vom Stamm Lactobacillus sake | EP93111153.8 | 1993-07-13 | EP0641857B1 | 2001-10-31 | Hammes, Walter Prof.Dr. |
| 153 | (BIFIDOBACTERIUM) IN THE TREATMENT OF INFLAMMATORY DISEASE | EP00900789.9 | 2000-01-17 | EP1141235A2 | 2001-10-10 | COLLINS, John, Kevin; O'SULLIVAN, Gerald, Christopher; O'MAHONY, Liam; SHANAHAN, Fergus |
| A strain of Bifidobacterium isolated from resected and washed human gastrointestinal tract is significantly immunomodulatory following oral consumption in humans. The strain is useful in the prophylaxis and/or treatment of undesirable inflammatory activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may also be due to cancer. | ||||||
| 154 | Rohpökelerzeugnis aus Fleisch und Verfahren zu seiner Herstellung | EP96100811.7 | 1996-01-20 | EP0724844B1 | 2001-05-30 | Klemend, Uwe, Dipl.-Ing.; Lembke, Gunther H., Dipl.-Ing.; Treitz, Patrick, Dipl.-Ing. |
| 155 | LACTIC ACID BACTERIUM-CONTAINING COMPOSITIONS, DRUGS AND FOODS | EP99923928.8 | 1999-06-04 | EP1082964A1 | 2001-03-14 | ISHIKAWA, Hiroshi, Wakamoto Pharmaceuti. Co., Ltd; SUZUKI, Nobuyuki, Wakamoto Pharmaceuti. Co., Ltd.; NAKAYA, Seigo, Wakamoto Pharmaceutical Co., Ltd.; HIRATA, Haruhisa, Wakamoto Pharmaceuti. Co., Ltd. |
The present invention has for its object to provide a lactic acid bacteria-containing composition which is conducive to an increased pharmacologic action of lactic acid bacteria showing such pharmacologic action in the digestive tract and/or the urogential organ and antagonizes the clearance of those lactic acid bacteria from the digestive tract and/or the urogenital organ. The present invention, therefore, is directed to a lactic acid bacteria-containing composition comprising lactic acid bacteria showing pharmacologic action in the digestive tract and/or the urogenital organ |
||||||
| 156 | PROCESS FOR THE MANUFACTURE OF PROBIOTIC CHEESE | EP99925245.5 | 1999-05-26 | EP1082021A1 | 2001-03-14 | ROSS, Reynolds Paul; FITZGERALD, Gerald Francis; COLLINS, John Kevin; O'SULLIVAN, Gerald Christopher; STANTON, Catherine Gerardine |
| A process for the manufacture of a probiotic cheese, such as Cheddar cheese, comprises adding a 0.05-0.5 % inoculum of a strain of Lactobacillus paracasei, which is non-pathogenic, acid and bile tolerant and adherent to human epithelial cells, as a starter adjunct to cheese milk, said L. paracasei strain being capable of growing during the ripening phase to a level of 107cfu/g or greater. The L. paracasei strains are found to grow and proliferate to high cell numbers (in excess of 108cfu/g) in the cheese over eight months of ripening, even when added at a relatively low inoculum. The presence of the L. paracasei strains is found to have negligible effects on cheese composition, flavour and aroma. | ||||||
| 157 | Rohpökelerzeugnis aus Fleisch und Verfahren zu seiner Herstellung | EP96100811.7 | 1996-01-20 | EP0724844A1 | 1996-08-07 | Klemend, Uwe, Dipl.-Ing.; Lembke, Gunther H., Dipl.-Ing.; Treitz, Patrick, Dipl.-Ing. |
Bei diesem Rohpökelerzeugnis aus Fleisch, insbesondere Lachsschinken, erfolgt die Pökelung mittels Zugabe von pulverisiertem Weichkäse, insbesondere Camembert, neben einer unverwechselbaren Aromatisierung erfolgt ein proteolytischer und lipolytischer Aufschluß des Außenbereiches des Fleischstückes, der eine optimale nachfolgende Beschimmelung mit Edelschimmelkulturen ermöglicht. Neben einer guten Haltbarkeit zeichnet sich das Erzeugnis durch ein neues, unverwechselbares, sehr feines Aroma aus. |
||||||
| 158 | UTILISATION DE LACTOBACILLUS SAKEI POUR LA BIOPRÉSERVATION DES PRODUITS DE LA MER | EP14722297.0 | 2014-04-18 | EP3047015A1 | 2016-07-27 | PODEUR, Gaëtan; LEROI, Françoise; PILET, Marie-France; PREVOST, Hervé |
| The invention relates to a strain of Lactobacillus sake called Lactobacillus sakei LHIS2885 strain, and to a strain derived from L. sakei LHIS2885. The invention also relates to the use of a strain of L. sakei, preferably the strain LHIS2885 or a strain derived from LHIS2885, for the preservation of food products, preferably products from the sea. | ||||||
| 159 | COMPOSITION COMPRENANT AU MOINS TROIS SOUCHES DIFFERENTES DE L. SAKEI POUR LA CONSERVATION DE PRODUITS COMESTIBLES | EP13750681.2 | 2013-08-13 | EP2892358B1 | 2016-01-20 | CHAILLOU, Stéphane; CHAMPOMIER-VERGES, Marie-Christine; ZAGOREC, Monique |
| 160 | FOOD COMPOSITIONS COMPROMISING DRIED PROBIOTICS, METHODS OF MANUFACTURE AND USES THEREOF | EP10711953.9 | 2010-03-26 | EP2410867A1 | 2012-02-01 | RUDOLPH, Marvin, J. |
| The present invention is directed to a food composition including an edible base mix component and a dried probiotic component which that may be stored at room temperature and converted to a frozen dessert with minimal effects to the viability of probiotics. Accordingly, a consumer ingesting the frozen dessert is provided with a beneficial amount of viable probiotics. Also provided herein are one or more methods for manufacturing the food compositions and using the subject food composition in frozen dessert products. | ||||||
